Massachusetts General Cancer Center

Boston, Massachusetts 02114

0 studies enrolling now · 2 studies all time

What they study most

Antibody-mediated Rejection, Cutaneous Squamous Cell Carcinoma

Studies at this site

• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Running, not enrolling
• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients — Stopped early